The Indian government has capped trade margins on 137 non-scheduled anti-cancer drug formulations at 30%, in a move intended to reduce the cost of cancer treatment and limit excessive mark-ups across the pharmaceutical supply chain. The National Pharmaceutical Pricing Authority (NPPA) issued the notification on October 17, 2026, with revised maximum retail prices (MRPs) scheduled to take effect from November 9. The government expects the measure to reduce prices by up to 70% for some medicines and generate annual savings of approximately ₹2,500 crore for patients.
The new rules extend price protection to cancer medicines that were previously outside the scheduled list of drugs subject to government-set ceiling prices. The notified list includes treatments containing medicines such as pembrolizumab, nivolumab, ribociclib, abemaciclib and osimertinib. The cap covers eligible branded and generic, domestic and imported, patented and non-patented formulations. However, the expected price reduction will vary by medicine, and the government has not said that every affected drug will become 70% cheaper.
Key Takeaways
- 137 formulations covered: The NPPA has capped trade margins on 137 non-scheduled anti-cancer drug formulations.
- Margin limit: The prescribed trade margin is capped at 30% of MRP, excluding GST, under the notified calculation.
- Effective date: Revised prices take effect on November 9, 2026.
- Potential price reductions: The government expects MRP reductions of approximately 20%–70%, depending on the existing price structure.
- Estimated savings: The measure is projected to save cancer patients around ₹2,500 crore annually.
- Supply safeguards: Manufacturers must maintain existing production levels and seek prior permission before reducing average monthly output.
- Previous precedent: A similar 2019 intervention reduced MRPs by up to 91% across 526 brands, according to government figures.
What Is the Government Changing?
The NPPA, which operates under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers, regulates medicine prices in India. Its latest order uses the government’s powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013, to intervene in the public interest.
The measure targets non-scheduled anti-cancer medicines, which are not subject to the same direct ceiling-price framework as scheduled formulations under the National List of Essential Medicines.
The government says the intervention is intended to address excessive trade margins that can substantially increase the final price paid by patients. It follows concerns about large differences between the price at which medicines enter the distribution chain and the MRP charged at the point of sale.
Under the new framework, the price calculation must follow the NPPA’s prescribed methodology. Manufacturers must submit their revised MRPs within seven days of the notification and ensure the revised prices are communicated to retailers, hospitals and other relevant channels.
The rule does not mean manufacturers must sell medicines at a loss or that all distribution margins have been eliminated. Instead, it limits the permitted trade margin under the notified formula while retaining a defined allowance for the distribution chain.
Why Cancer Medicine Prices Are Under Scrutiny
Cancer treatment can involve expensive medicines that patients need over extended periods. Depending on the type and stage of cancer, treatment may include chemotherapy, immunotherapy, targeted therapy or combinations of medicines.
For patients paying out of pocket, the cost of medicines can represent a substantial financial burden alongside hospital fees, diagnostic tests, travel and other expenses.
The government cited NPPA market analysis indicating that non-scheduled anti-cancer drugs carried average trade mark-ups of approximately 170%, with some cases reaching 700%. Such figures refer to mark-ups observed in the market, not a universal margin applied to every cancer medicine.
The authority also identified differences in prices across retail pharmacies, hospital pharmacies and online pharmacy channels. These variations can make it difficult for patients and families to understand whether they are paying a competitive price.
The new cap is intended to narrow the gap between acquisition costs and the final price charged to patients. Its effectiveness will depend on implementation, compliance and whether the revised prices are consistently reflected across sales channels.
How the 30% Trade Margin Cap Works
The distinction between a trade margin and a mark-up is important to understanding the new rules.
A mark-up measures how much a selling price exceeds a purchase cost. A trade margin, by contrast, measures the margin as a proportion of the selling price. These percentages are not interchangeable.
The NPPA’s notified framework caps the trade margin at 30% of the MRP, excluding GST. This corresponds to a mark-up of approximately 42.86% on the price to stockist or price to distributor under the prescribed calculation.
| Item | What the rule means |
|---|---|
| Trade margin cap | 30% of MRP, excluding GST |
| Equivalent mark-up | Approximately 42.86% on the relevant stockist/distributor price |
| Effective date | November 9, 2026 |
| Expected MRP reduction | Approximately 20%–70%, depending on the medicine |
| Manufacturer reporting | Revised MRPs must be submitted within seven days |
| Existing lower prices | Must be maintained where the current MRP is below the recalculated level |
The cap is therefore not a blanket instruction to reduce every medicine’s price by 30%. The actual revision depends on the existing price structure and the prescribed formula.
For example, if a formulation currently carries a very large mark-up between its acquisition price and MRP, the revised ceiling may be substantially lower. A medicine already sold at a relatively low price may require a much smaller change or no increase at all.
The notification also requires manufacturers to maintain existing prices where their current MRPs are lower than the amount calculated under the new framework. This provision is intended to prevent the revised formula from being used to increase prices for products already sold more cheaply.
Which Cancer Medicines Are Included?
The notified list covers 137 formulations selected for the intervention following expert review. It includes several high-cost oncology medicines used in immunotherapy and targeted cancer treatment.
Examples reported in coverage of the notification include:
- Pembrolizumab, an immunotherapy used for certain cancers.
- Nivolumab, another immunotherapy used in specific cancer indications.
- Ribociclib and palbociclib, targeted therapies used in certain breast cancer treatment regimens.
- Osimertinib, a targeted medicine used for particular forms of lung cancer.
- Olaparib, a targeted treatment used for selected cancers.
- Abemaciclib, a medicine used in certain breast cancer treatment settings.
- Bevacizumab and atezolizumab, which are used for specific cancer indications.
The inclusion of a medicine in this list does not mean it is suitable for every cancer patient. Treatment choices depend on the diagnosis, cancer characteristics, clinical evidence and a treating specialist’s assessment.
The price-control order applies to the formulations identified under the notification, including eligible strengths, dosage forms and routes of administration as specified in the rules. The NPPA may update the list periodically.
Patients should check the exact formulation, strength and brand when comparing prices. Similar medicine names do not necessarily mean that products are interchangeable.
How Much Could Patients Save?
The government expects the revised price structure to reduce the MRPs of affected medicines by approximately 20%–70%. The actual reduction will differ across products because existing mark-ups vary.
The following examples illustrate how different percentage reductions would affect a medicine’s current price. They are calculations, not confirmed revised prices for specific brands.
| Current MRP | After a 20% reduction | After a 50% reduction | After a 70% reduction |
|---|---|---|---|
| ₹5,000 | ₹4,000 | ₹2,500 | ₹1,500 |
| ₹10,000 | ₹8,000 | ₹5,000 | ₹3,000 |
| ₹25,000 | ₹20,000 | ₹12,500 | ₹7,500 |
| ₹50,000 | ₹40,000 | ₹25,000 | ₹15,000 |
| ₹1,00,000 | ₹80,000 | ₹50,000 | ₹30,000 |
For a patient who requires repeated purchases of an affected medicine, even a smaller reduction could produce meaningful savings over a course of treatment. For high-priced formulations, a large reduction could lower the amount paid at each purchase considerably.
However, the total cost of cancer treatment includes more than medicines. Hospital charges, medical procedures, tests, consultations and other treatment-related expenses may remain unchanged. The price cap should therefore be understood as one measure to reduce treatment costs, rather than a guarantee that the total bill will fall by the same percentage.
Why the Government Estimates ₹2,500 Crore in Annual Savings
The government estimates that the intervention could save patients approximately ₹2,500 crore each year. That figure is a projection based on the expected effect of the new pricing rules across the affected market.
The reported annual turnover of cancer medicines in India is around ₹12,500 crore. Scheduled cancer drugs, which already face direct price regulation, account for a smaller portion of that market. The new intervention targets non-scheduled formulations where trade mark-ups have been identified as a significant source of higher prices.
Actual savings will depend on the prices manufacturers submit, the quantities sold, compliance by distributors and hospitals, and the medicines patients use.
The projection should not be interpreted as an equal cash benefit for every cancer patient. Some patients may use medicines covered by the notification, while others may receive treatment involving drugs outside the list. The savings will also vary with the treatment regimen and purchasing channel.
The government’s estimate nevertheless indicates the potential scale of the intervention if revised prices are implemented across the affected market.
How the 2019 Price-Control Exercise Provides a Precedent
The latest intervention builds on a similar exercise in 2019, when the government capped trade margins on 42 selected non-scheduled anti-cancer medicines.
According to government figures, that intervention led to MRP reductions of up to 91% across 526 brands and estimated annual savings of approximately ₹984 crore.
The earlier exercise provided a precedent for using trade-margin regulation to address high prices in parts of the cancer medicine market. The current measure covers a broader list of 137 formulations.
However, the outcomes of the two exercises may differ because the medicines, market structures and price levels are not identical. The latest savings estimate remains a projection, and its realised effect will need to be assessed after the revised prices take effect.
How the Government Plans to Prevent Medicine Shortages
Lower prices can improve affordability, but regulators also need to ensure that manufacturers continue supplying essential medicines.
The NPPA’s notification requires manufacturers to maintain existing production levels for the listed formulations. Companies intending to reduce average monthly output must seek prior permission, while those planning to discontinue production must inform the authority.
Manufacturers must also communicate revised prices widely so patients, retailers and hospitals know which MRPs apply from November 9.
These safeguards are important because a price reduction would offer limited benefit if affected medicines became difficult to obtain. State drug controllers and other authorities are expected to monitor compliance across manufacturers, distributors, retailers and hospitals.
The effectiveness of the rules will depend on whether the new prices are reflected accurately in bills and whether supply remains reliable after implementation.
The Bigger Picture
The government’s 30% trade-margin cap extends price protection to a wider range of non-scheduled cancer medicines and attempts to reduce excessive mark-ups without removing all legitimate distribution margins. With 137 formulations covered and annual savings projected at ₹2,500 crore, the intervention could make some expensive treatments more affordable for patients who pay out of pocket.
The ultimate impact will depend on how much individual MRPs fall, whether hospitals and retailers follow the revised prices and whether manufacturers maintain adequate supplies. The November 9 implementation date will be the next important milestone, after which patients and healthcare providers can assess the actual price changes across the notified medicines.
Looking Ahead
Manufacturers must submit revised MRPs within seven days of the notification and prepare to apply the new prices from November 9, 2026. Patients should check updated price lists and itemised bills for the exact medicine and formulation they use. The government has also required manufacturers to maintain production levels, making availability an important part of the implementation process.
Over the longer term, the NPPA’s monitoring will determine whether the price reductions translate into the projected savings without disrupting supply. The intervention could provide a model for addressing excessive mark-ups in other parts of healthcare, but any wider action would depend on the relevant market evidence and regulatory decisions. For now, the immediate focus is on implementing the notified cap and ensuring that patients actually benefit from the revised prices.
Frequently Asked Questions
1. What has the government announced for cancer medicines?
The NPPA has capped trade margins on 137 non-scheduled anti-cancer drug formulations at 30% of MRP, excluding GST, under the notified calculation.
2. When will the revised cancer drug prices take effect?
The revised prices are scheduled to take effect on November 9, 2026.
3. Will all 137 cancer medicines become 70% cheaper?
No. The government expects price reductions of approximately 20%–70%, depending on each medicine’s existing price structure. The maximum projected reduction will not apply uniformly.
4. Which medicines are included?
The notified list includes formulations containing medicines such as pembrolizumab, nivolumab, ribociclib, palbociclib, osimertinib and olaparib. Patients should check the official list for the exact formulation and strength.
5. How much will patients save?
The government estimates annual savings of approximately ₹2,500 crore across the affected market. Individual savings will depend on the medicine, the price reduction and how frequently it is purchased.
6. Will the price cap affect medicine availability?
The notification requires manufacturers to maintain existing production levels. Companies planning to reduce average monthly output must seek prior permission, and those planning to discontinue listed formulations must inform the NPPA.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
